A Phase 3 interventional study of TransCon PTH and Placebo in Hypoparathyroidism, Endocrine System Diseases and Parathyroid Diseases, sponsored by Ascendis Pharma Bone Diseases A/S. Completed at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ascendis Pharma Bone Diseases A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.
Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 7th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 3, and was the 26th registered.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
Browse Hypoparathyroidism studies →8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Calcilytix Therapeutics, Inc., a BridgeBio company · Sites in United States, Canada, Japan
Ages 16+
MBX Biosciences · Sites in United States, Canada
Ages 18+
Ascendis Pharma Bone Diseases A/S · Sites in United States
Ages 18+
Ascendis Pharma A/S · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 14 · Phase 4 3
First in 1991; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Median enrollment 41 across the 34 interventional studies, 95 across the 9 observational. Of the 29 that completed or were terminated, 22 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Ascendis Pharma Bone Diseases A/S is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ascendis Pharma Bone Diseases A/S has 3 studies filed under Hypoparathyroidism — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypoparathyroidism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081997Phase 3Ascendis Pharma Bone Diseases A/SA Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | 2027-06 |
| NCT05793853Columbia UniversityHypoparathyroidism Natural History Study | 2026-12 |
| NCT07264634Ascendis Pharma A/SA Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Hypoparathyroidism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During the first 26 weeks of the trial, participants were randomly assigned to one of two groups: one group received TransCon PTH and one group received placebo. All participants started with study drug at a dose of 18 mcg/day and were individually and progressively titrated to an optimal dose in dose increments of 3 mcg/day. TransCon PTH or placebo were administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors knew who had been assigned to each group. After the 26 weeks, participants continued in the trial as part of a long-term extension study. During the extension, all participants received TransCon PTH, with the dose adjusted to their individual needs. This was a global trial that was conducted in the United States, Canada, Germany, Denmark, Norway, Italy, and Hungary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Requirement for doses of SoC (e.g., calcitriol, alfacalcidol, calcium supplements) at or above a minimum threshold:
Optimization of supplements prior to randomization to achieve the target serum levels of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection and titrated to an optimal dose
Combination Product: TransCon PTH
Placebo for TransCon PTH delivered once daily by subcutaneous injection
Combination Product: Placebo
TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Efficacy - Primary Endpoint During the Blinded Period
The primary endpoint was a multi-component endpoint that included the percentage of participants who met the following criteria at 26 weeks of blinded treatment: 1) albumin-adjusted serum calcium measured within 4 weeks prior to and on Week 26 visit within the normal range (8.3 to 10.6 mg/dL), and 2) independence from active vitamin D within 4 weeks prior to Week 26 visit (i.e., all daily standing dose of active vitamin D equal to zero AND use of PRN ≤7 days during the 4 weeks), and 3) independence from therapeutic doses of calcium within 4 weeks prior to Week 26 visit (i.e., average daily standing dose of elemental calcium ≤600 mg AND use of PRN doses on ≤7 days during the 4 weeks), and 4) no increase in prescribed study drug within 4 weeks prior to Week 26 visit.
Time frame: 26 weeks
Change From Baseline to Week 26 in HPES Symptom - Physical Domain Score
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Physical Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related physical symptoms.
Time frame: 26 weeks
Change From Baseline to Week 26 in HPES Symptom - Cognitive Domain Score
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Cognitive Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related cognitive symptoms.
Time frame: 26 weeks
Change From Baseline to Week 26 in HPES Impact - Physical Functioning Domain Score
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Physical Functioning Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in physical functioning health-related quality of life.
Time frame: 26 weeks
Change From Baseline to Week 26 in HPES Impact - Daily Life Domain Score
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Daily Life Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in daily health-related quality of life.
Time frame: 26 weeks
Change From Baseline to Week 26 in SF-36 Physical Functioning Subscale Score
Change from baseline in the 36-item Short Form Survey (SF-36) Physical Functioning subscale score, a generic health survey, at 26 weeks of treatment. The Physical Functioning subscale uses a range of 19-57.6 and values represent the change in scores from baseline. An increase in SF-36 score denotes an improvement in physical functioning health-related quality of life.
Time frame: 26 weeks
Overall, 84 subjects were randomized and 82 subjects were dosed. Enrollment of subjects occurred in seven countries: Canada, Denmark, Germany, Italy, Hungary, Norway, and the United States.
| Milestone | Double Blind: TransCon PTH | Double Blind: Placebo | Open-Label Extension Period: TransCon PTH |
|---|---|---|---|
| Started | 61 | 21 | 0 |
| Completed | 60 | 19 | 0 |
| Not completed | 1 | 2 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Double Blind: TransCon PTH | Double Blind: Placebo | Open-Label Extension Period: TransCon PTH |
|---|---|---|---|
| Started | 0 | 0 | 79 |
| Completed | 0 | 0 | 73 |
| Not completed | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
The primary endpoint was a multi-component endpoint that included the percentage of participants who met the following criteria at 26 weeks of blinded treatment: 1) albumin-adjusted serum calcium measured within 4 weeks prior to and on Week 26 visit within the normal range (8.3 to 10.6 mg/dL), and 2) independence from active vitamin D within 4 weeks prior to Week 26 visit (i.e., all daily standing dose of active vitamin D equal to zero AND use of PRN ≤7 days during the 4 weeks), and 3) independence from therapeutic doses of calcium within 4 weeks prior to Week 26 visit (i.e., average daily standing dose of elemental calcium ≤600 mg AND use of PRN doses on ≤7 days during the 4 weeks), and 4) no increase in prescribed study drug within 4 weeks prior to Week 26 visit.
| Percentage of participants | TransCon PTH | Placebo |
|---|---|---|
| Efficacy - Primary Endpoint During the Blinded Period | 78.7 (66.3 to 88.1) | 4.8 (0.1 to 23.8) |
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Physical Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related physical symptoms.
| units on a scale | TransCon PTH | Placebo |
|---|---|---|
| Change From Baseline to Week 26 in HPES Symptom - Physical Domain Score | -21.01 (-25.41 to -16.60) | -4.81 (-15.22 to 5.59) |
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Cognitive Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism disease related cognitive symptoms.
| units on a scale | TransCon PTH | Placebo |
|---|---|---|
| Change From Baseline to Week 26 in HPES Symptom - Cognitive Domain Score | -20.49 (-25.67 to -15.31) | -6.16 (-15.92 to 3.60) |
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Physical Functioning Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in physical functioning health-related quality of life.
| units on a scale | TransCon PTH | Placebo |
|---|---|---|
| Change From Baseline to Week 26 in HPES Impact - Physical Functioning Domain Score | -18.29 (-23.59 to -12.99) | -1.01 (-12.40 to 10.38) |
Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Daily Life Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment. The measure uses a scale of 0-100 and values represent the change in scores from baseline. A decrease in HPES score denotes an improvement in daily health-related quality of life.
| units on a scale | TransCon PTH | Placebo |
|---|---|---|
| Change From Baseline to Week 26 in HPES Impact - Daily Life Domain Score | -17.65 (-22.39 to -12.91) | -0.36 (-12.19 to 11.46) |
Change from baseline in the 36-item Short Form Survey (SF-36) Physical Functioning subscale score, a generic health survey, at 26 weeks of treatment. The Physical Functioning subscale uses a range of 19-57.6 and values represent the change in scores from baseline. An increase in SF-36 score denotes an improvement in physical functioning health-related quality of life.
| units on a scale | TransCon PTH | Placebo |
|---|---|---|
| Change From Baseline to Week 26 in SF-36 Physical Functioning Subscale Score | 5.29 (3.47 to 7.10) | 0.12 (-4.64 to 4.89) |
Collected over From Week 0 to Week 26 for double-blind treatment period and up to Week 182 for open label extension (OLE). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind: TransCon PTH | 1/61 (1.6%) | 5/61 (8.2%) | 50/61 (82%) |
| Double Blind: Placebo | 0/21 (0%) | 2/21 (9.5%) | 20/21 (95.2%) |
| Total TransCon PTH Period | 1/80 (1.3%) | 20/80 (25%) | 72/80 (90%) |
| Event | Double Blind: TransCon PTH | Double Blind: Placebo | Total TransCon PTH Period |
|---|---|---|---|
| HypocalcaemiaMetabolism and nutrition disorders | 1/61 | 0/21 | 5/80 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/61 | 1/21 | 0/80 |
| Bipolar disorderPsychiatric disorders | 0/61 | 1/21 | 0/80 |
| Rectal haemorrhageGastrointestinal disorders | 1/61 | 0/21 | 2/80 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/61 | 0/21 | 2/80 |
| PneumoniaInfections and infestations | 0/61 | 0/21 | 2/80 |
| Cardiac arrestCardiac disorders | 1/61 | 0/21 | 1/80 |
| ColitisGastrointestinal disorders | 1/61 | 0/21 | 1/80 |
| Endometrial disorderReproductive system and breast disorders | 0/61 | 0/21 | 1/80 |
| ProctalgiaGastrointestinal disorders | 0/61 | 0/21 | 1/80 |
| Event | Double Blind: TransCon PTH | Double Blind: Placebo | Total TransCon PTH Period |
|---|---|---|---|
| COVID-19Infections and infestations | 1/61 | 0/21 | 40/80 |
| HypocalcaemiaMetabolism and nutrition disorders | 5/61 | 9/21 | 15/80 |
| Injection site reactionGeneral disorders | 19/61 | 0/21 | 20/80 |
| ParaesthesiaNervous system disorders | 12/61 | 3/21 | 21/80 |
| FatigueGeneral disorders | 9/61 | 5/21 | 18/80 |
| HeadacheNervous system disorders | 13/61 | 2/21 | 19/80 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 7/61 | 3/21 | 17/80 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/61 | 2/21 | 13/80 |
| HypertensionVascular disorders | 3/61 | 3/21 | 12/80 |
| NauseaGastrointestinal disorders | 7/61 | 2/21 | 12/80 |
| Age, Continuous(years) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Mean | 49.0 ± 13.13 | 47.3 ± 11.43 | 48.6 ± 12.67 |
| Sex: Female, Male(Participants) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Female | 46 | 18 | 64 |
| Male | 15 | 3 | 18 |
| Race/Ethnicity, Customized(Participants) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Asian | 3 | 2 | 5 |
| White | 57 | 19 | 76 |
| Other | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Not Hispanic or Latino | 57 | 18 | 75 |
| Not Reported | 3 | 1 | 4 |
| Unknown | 1 | 2 | 3 |
| Height(cm) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Mean | 168.22 ± 8.353 | 166.67 ± 8.831 | 167.82 ± 8.450 |
| Weight(kg) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Mean | 77.18 ± 17.335 | 81.61 ± 15.631 | 78.31 ± 16.932 |
| Body Mass Index(kg/m^2) | TransCon PTH | Placebo | Total |
|---|---|---|---|
| Mean | 27.27 ± 5.813 | 29.47 ± 5.691 | 27.83 ± 5.828 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2021 to primary completion in Jan 2022, 10 months.
Results were first posted in Feb 2025, 3 years 1 month after primary completion. A results delay was requested in Aug 2022.
Of 15 phase 3 interventional studies under Hypoparathyroidism, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 86. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palopegteriparatide
Ascendis Pharma Bone Diseases A/S